Related Experiment Video
Updated: Feb 16, 2026
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
Alexandra Pender1, Robin L Jones1,2
1Sarcoma Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust.
Abstract:
The outcome of patients with unresectable or metastatic soft tissue sarcoma (STS) remains poor with few treatment options. A number of randomized trials in the first-line setting have shown no difference in overall survival between combination anthracycline schedules and single-agent doxorubicin. A Phase Ib/randomized Phase II trial of doxorubicin with or without the platelet-derived growth factor receptor-α (PDGFRα)-blocking antibody, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. The results of this trial led to the approval of olaratumab in combination with doxorubicin in adult anthracycline-naïve unresectable STS. In this review, we discuss the potential role of PDGFRα signaling, early clinical data with olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas.
Insights
Adding olaratumab to doxorubicin significantly improved overall survival for patients with unresectable soft tissue sarcoma (STS). This combination therapy offers a new option for advanced STS, addressing poor outcomes and limited treatments.
Area of Science:
- Oncology
- Medical Research
- Pharmacology
Background:
- Unresectable or metastatic soft tissue sarcoma (STS) has a poor prognosis with limited therapeutic choices.
- Previous first-line treatments, including anthracycline combinations and single-agent doxorubicin, have not improved overall survival.
- Platelet-derived growth factor receptor-α (PDGFRα) signaling is implicated in sarcoma development.
Purpose of the Study:
- To review the role of PDGFRα signaling in sarcomas.
- To discuss early clinical data and trial results for olaratumab in sarcoma treatment.
- To evaluate the efficacy of olaratumab in combination with doxorubicin for unresectable STS.
Main Methods:
- Review of early clinical data and a Phase Ib/randomized Phase II trial.
- Analysis of patient outcomes in the first-line setting for unresectable STS.
- Investigation of olaratumab, a PDGFRα-blocking antibody, in combination with doxorubicin.
Main Results:
- A Phase Ib/randomized Phase II trial showed a significant improvement in median overall survival with olaratumab plus doxorubicin compared to doxorubicin alone.
- These findings supported the approval of olaratumab in combination with doxorubicin for adult anthracycline-naïve unresectable STS.
- Ongoing trials continue to explore the efficacy of olaratumab in various sarcoma settings.
Conclusions:
- Olaratumab in combination with doxorubicin represents a significant advancement in the treatment of unresectable STS.
- Targeting PDGFRα signaling offers a promising therapeutic strategy for patients with advanced soft tissue sarcomas.
- Further research and ongoing trials are crucial to fully elucidate the potential of olaratumab in sarcoma management.
